N/A Completed N=18

The Effect of Growth Hormone Replacement on Liver Fat

Growth Hormone, Recombinant · fatty liver

Source: ClinicalTrials.gov NCT00774579 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2019

Primary outcomePrimary: Intrahepatocellular Lipid (IHCL) Content — -0.63; 0.11 % change from baseline — p=0.6

Summary

We will examine a cohort of growth hormone deficient adults starting growth hormone (GH) replacement. The purpose of this study is to determine whether GH replacement reduces the fat content of the liver. To compare the results we will include growth hormone deficient patients who do not start GH replacement as controls.

Outcome Measures

Outcome	Result	p-value
PRIMARY Intrahepatocellular Lipid (IHCL) Content	-0.63; 0.11	0.6
SECONDARY Total Adipose Tissue	-1.8; 0.24	0.1

Eligibility Criteria

Inclusion Criteria

20-70 years of age
Growth hormone deficiency, with (cohort 1) or without (cohort 2) planned growth hormone (GH) replacement
clinically stable

Exclusion Criteria

known hepatic disease
Acromegaly
Diabetes mellitus
growth hormone replacement within the last 12 months
cushing's disease, if not cured for at least 12 months
any contraindication to MR studies as set out in the MR safety questionnaire

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00774579). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.